Lyophilization USA Conference 2018

SMi Group15 - 16 November 2018, New Jersey, USA.
16% of the top 100 pharmaceutical drugs and 35% of biologic drugs are lyophilized. With more than 30% of the FDA-approved parenterals lyophilized and soon more than half injectable drugs to require lyophilization there is ample room for standardization and expansion of the lyophilization process in pharmaceuticals.

The 4th Annual Lyophilization USA conference will be analysing technological advantages, regulatory challenges and unmet needs within lyophilization.

Day 1 of the Conference (November 15) will be covering Novel Techniques and Advances, Regulatory Challenges and Analytical Processes; Continuous monitoring of sublimation rate for individual containers & Reconstitution challenges of lyophilized highly concentrated protein products; Freeze dryer characterization and application to drug product development and scale up; Formulation and excipient selection for lyo product development of vaccines

Day 2 of the Conference (November 16) will be focusing on challenges that process of lyophilization brings to pharmaceutical and biotechnology companies; Oncobiologics on Freezing of biologics formulations - impact on stability; Panel Discussion on Process modelling and simulation; and also looking into alternatives to conventional methods with the Keynote Address on vacuum-foam drying and key action points on future directions in lyophilization

Featured Speakers

  • Alex Langford - Pfizer
  • Colin Campbell - Elusys Therapeutics
  • Dena Flamm - Optima Machinery Corporation
  • Fabrice Schlegel - Amgen
  • Hiten Gutka - Oncobiologics
  • Morrisa Jones - Merck
  • Alina Alexeenko - Purdue University
  • Rui Fang - Merck Research Laboratories
  • Sushma Kommareddy - Takeda
  • Timothy McCoy - Sanofi

Enhance your knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze dryer technologies including spray drying, spin freeze-drying and microwave drying at the Workshop A on November 14 hosted by Alexander Tambovzev and Dena Flamm of Optima Pharma

Are you new to the area of freeze-drying/lyophilization? Sign up to attend the Workshop B on November 14 hosted by Robin Bogner, University of Connecticut and gain an understanding of the essential aspects of freeze-drying.

Further details at http://www.lyophilization-usa.com/wpnWL

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

Johnson & Johnson statement on COVID-19 vaccin…

The safety and well-being of the people who use our products is our number one priority. We are aware of an extremely rare disorder involving people with blood clots in c...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

GSK and Vir Biotechnology announce EMA review of d…

GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational...

Phase III prevention trial showed subcutaneous adm…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail ...

Amgen successfully completes acquisition of Five P…

Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Pr...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Valneva switches focus to bilateral discussions to…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 2...

Patients who are obese or overweight are at risk f…

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mec...

Massive fragment screen points way to new SARS-CoV…

New research published in Science Advances provides a template for how to develop directly-acting antivirals with novel modes of action, that would combat COVID-19 by sup...